Predictive values of the expression of ERCC1 and TS for FOLFOX adjuvant chemotherapy in gastric cancer
10.3969/j.issn.1002-3070.2014.03.009
- VernacularTitle:ERCC1和 TS 表达对胃癌术后患者改良FOLFOX7方案辅助化疗疗效的预测
- Author:
Jiao WANG
;
Hongwei SUN
;
Xing LIU
;
Baoli QIN
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
ERCC1;
TS;
Chemotherapy
- From:
Practical Oncology Journal
2014;(3):233-238
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the expression of the excision repair cross complementing 1 ( ERCC1 ) and thymidylate synthase ( TS) in gastric cancer and to investigate the correlation between the ERCC 1 and TS ex-pression with the efficacy of FOLFOX adjuvant chemotherapy in gastric cancer patients .Methods A total of 73 gastric cancer patients received modified FOLFOX adjuvant chemotherapy .Real-time PCR was used to investi-gate the expression of ERCC 1 and TS in gastric cancer tissue .We also studied their correlation and association with prognosis .Results ERCC1 and TS expressed in gastric cancer tissues with the positive rate were 42 .5%(31/73)and 61.6%(45/73).There was no significant correlation between the ERCC 1 or TS expression and the clinical features .In this study ,the median of RFS and MST were 16 months and 27 months in patients with ER-CC1-negtive expression,9 months and 16months in patients with ERCC1-positive expression,the median of RFS and MST were significantly different in the two groups (P=0.000,P=0.002).There were no statistical differences on TS expression pattern in either median of RFS or MST (P=0.10,P=0.71).Conclusion The ex-pression of ERCC1 may be useful in prediction of the clinical outcome in gastric cancer patients who treated with FOLFOX7 adjuvant chemotherapy .Patients with ERCC1-negtive expression may benefit from the therapy .
